Single-day treatment for orolabial and genital herpes: A brief review of pathogenesis and pharmacology

Therapeutics and Clinical Risk Management

Volumn 4, Issue 2, 2008, Pages 409-417

  Modi, Sapna ^a   Van, Livia ^a   Gewirtzman, Aron ^b   Mendoza, Natalia ^b   Bartlett, Brenda ^b   Tremaine, Anne Marie ^b   Tyring, Stephen ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CLINICAL STUDIES   (United States)

^c University of Texas Health Science Center at Houston   (United States)

Author keywords

Antiviral; Famciclovir; Genital herpes; Orolabial herpes; Patient initiated episodic therapy; Single day

Indexed keywords

ACICLOVIR; BEHENYL ALCOHOL; FAMCICLOVIR; NUCLEOSIDE ANALOG; PENCICLOVIR; PLACEBO; VALACICLOVIR;

ABDOMINAL PAIN; ANTIVIRAL THERAPY; CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SELECTIVITY; DRUG TARGETING; GASTROINTESTINAL TOXICITY; GENITAL HERPES; HEALING; HERPES LABIALIS; HERPES SIMPLEX VIRUS; HUMAN; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PATHOGENESIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; SINGLE DRUG DOSE; SYMPTOMATOLOGY; TREATMENT DURATION; VIRUS REPLICATION;

EID: 44049094973     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Aoki FY, Tyring S, Diaz-Mitoma F, et al. 2006. Single-day, patient-iniated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis, 24:8-13.
2. Bacon TH. 1996. Famciclovir, from the bench to the patient - a comprehensive review of preclinical data. Int J Antimicrob Agents, 7:119-34.
3. Bacon TH, Levin MJ, Leary JJ, et al. 2003. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microb Rev, 16:114-28.
4. Baker D, Eisen D. 2003. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. Cutis, 71:239-42.
5. Boyd MR, Bacon TH, Sutton D, et al. 1987. Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture. Antimicrob Agents Chemother, 31:1238-42.
6. Chosidow O, Drouault Y, Leconte-Veyriac F, et al. 2001. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups randomized, double-blind clinical trial. Br J Dermatol, 144:818-824.
7. Corey L, Wald A, Patel R, et al. 2004. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med, 350:11-20.
8. Crumpacker C. 1996. The pharmacological profile of famciclovir. Semin Dermatol, 15:14-26.
9. Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. 1998. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. Collaborative Famciclovir Genital Herpes Research Group. JAMA, 280:887-92.
10. Earnshaw DL, Bacon TH, Darlison SJ, et al. 1992. Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus. Antimicrob Agents Chemother, 36:2747-57.
11. Freeman EE, Weiss HA, Glynn JR, et al. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. Aids, 20:73-83.
12. Ilsley DD, Lee S-H, Miller WH, et al. 1995. Acyclic guanosine analogs inhibit DNA polymerases α, δ, and ̇with very different potencies and have unique mechanisms of action. Biochemistry, 34:2504-10.
13. Jensen LA, Hoehns JD, Squires CL. 2004. Oral antivirals for the acute treatment of recurrent herpes labialis. Ann Pharmacother, 38:705-709.
14. Jungmann E. 2006. Genital herpes. Clin Evid, Aug:1-13.
15. Larsson A, Stenberg K, Ericson A-C, et al. 1986. Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir. Antimicrob Agents Chemother, 30:598-605.
16. Leone PA, Trottier S, Miller JM. 2002. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. Clin Infect Dis, 34:958-62.
17. Lorette G, Crochard A, Mimaud V, et al. 2006. A survey on the prevalence of orofacial herpes in France: the INSTANT Study. J Am Acad Dermatol, 55:225-,32.
18. Nadelman CM and Newcomer VD. 2000. Herpes simplex virus infections: new treatment approaches make early diagnosis even more important. Postgrad Med, 107:189-200.
19. Ormrod D, Goa K. 2000. Valaciclovir: a review of its use in the management of herpes zoster. Drugs, 59:1317-40.
20. Pue MA, Benet LZ. 1993. Pharmacokinetics of famciclovir in man. Antivir Chem Chemother, 4:47-55.
21. Pue MA, Pratt SK, Fairless AJ, et al. 1994. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother, 33:119-27.
22. Raborn GW, Martel AY, Lassonde M, et al. 2002. Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials. J Am Dent Assoc, 133:303-9.
23. Reardon JE, Spector T. 1989. Herpes simplex virus type 1 DNA polymerase: mechanism of inhibition by acyclovir triphosphate. J Biol Chem, 264:7405-11.
24. Reichman RC, Badger GJ, Guinan ME, et al. 1983. Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial. J Inftct Dis, 147:336-40.
25. Reichman RC, Badger GJ, Mertz GJ, et al. 1984. Treatment of recurrent genital herpes simplex infections with oral acyclovir: a controlled trial. JAMA, 251:2103-7.
26. Reitano M, Tyring S, Lang W, et al. 1998. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group. J Infect Dis, 178:603-10.
27. Sacks SL, Aoki FY, Diaz-Mitoma F, et al. 1996. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes: a randomized, double-blind multicenter trial. JAMA, 276:44-9.
28. Sacks SL, Thisted RA, Jones TM, et al. 2001. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol, 45:222-30.
29. Simpson D and Lyseng-Williamson KA. 2006. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs, 66:2397-416.
30. Smith JS and Robinson NJ. 2002. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J Infect Dis, 186:S3-S28.
31. Spruance SL, Bodsworth N, Resnick H, et al. 2006. Single-dose, patient-initiated famciclovir: A randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol, 55:47-53.
32. Spruance SL, Jones TM, M.M. B, et al. 2003. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother, 43:1072-80.
33. Spruance SL, Nett R, Marbury T, et al. 2002. Acyclovir Cream for Treatment of Herpes Simplex Labialis: Results of Two Randomized, Double-Blind, Vehicle-Controlled, Multicenter Clinical Trials. Antimicrob Agents Chemother, 46:2238-43.
34. Spruance SL, Rea TL, Thoming C, et al. 1997. Penciclovir Cream for the Treatment of Herpes Simplex Labialis: A Randomized, Multicenter, Double-blind, Placebo-Controlled Trial. JAMA, 277:1374-479.
35. Tyring S, Berger T, Yen-Moore A, et al. 2006. Single-day therapy for recurrent genital herpes. Am J Clin Dermatol, 7:209-11.
36. Tyring SK, Douglas JM Jr, Corey L, et al. 1998. A randomized, placebo-controlled comparison of oral valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol, 134:185-91.
37. Vere Hodge RA and Cheng Y-C. 1993. The mode of action of penciclovir. Antivir Chem Chemother, 4:13-24.
38. Vere Hodge RA, Perkins RM. 1989. Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrob Agents Chemother, 33:223-9.
39. Wald A, Carrell D, Remington M, et al. 2002. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clini Infect Dis, 34:944-8.
40. Whitley R, Diaz-Mitoma F, Hamed K. 2006. Single-day famciclovir therapy for recurrent genital herpes. Curr Medl Res Opin, 22:1307-10.
41. Whitley RJ, Kimberlin DW and Roizman B. 1998. Herpes simplex viruses. Clin Infect Dis, 26:541-53.
42. Wolff K, Johnson RA, Suurmond D. 2005. Nongenital herpes simplex virus infection. Fitzpatrick's color atlas and synopsis of clinical dermatology. McGraw-Hill. pp. 802-5.
43. Xu F, Sternberg MR, Kottiri BJ, et al. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA, 296:964-73.